Sign in Subscribe
Cleveland Clinic

Faricimab Shows Promise in Treating Diabetic Macular Edema

Strategic Insights

— 1 min read

A new report from researchers at Cleveland Clinic has found that switching to intravitreal faricimab injections (IFIs) from prior anti-vascular endothelial growth factor (anti-VEGF) therapy results in significant improvements in diabetic macular edema (DME) patients. The study, published in Ophthalmic Surgery, Lasers and Imaging Retina, analyzed the short-term outcomes of switching to IFIs in 62 eyes from 41 patients with DME. The results showed that after receiving three IFIs, treatment intervals increased significantly, and visual acuity remained stable.

Key Takeaways:

  • The study evaluated the short-term outcomes of switching to IFIs from prior anti-VEGF therapy in DME patients, with a mean follow-up time of 36.4 +/- 14.4 weeks.
  • A total of 62 eyes from 41 patients were analyzed, with 17 eyes (27.4%) switched back to their prior anti-VEGF agent due to suspected IFI-related uveitis.
  • The study found that faricimab appears to be a viable option for some DME patients who require a change in anti-VEGF therapy.
  • The mean increase in treatment interval was 3.2 weeks, and visual acuity remained stable with a mean of 63.2 vs 64.4 approximate ETDRS letters.
  • The study provides evidence that switching to IFIs can improve treatment outcomes for DME patients.

Statistics:

  • 62 eyes from 41 patients with DME were analyzed in the study.
  • The mean follow-up time was 36.4 +/- 14.4 weeks.
  • 17 eyes (27.4%) were switched back to their prior anti-VEGF agent.
  • The mean increase in treatment interval was 3.2 weeks.
  • Visual acuity remained stable with a mean of 63.2 vs 64.4 approximate ETDRS letters.

Sources:

  • Early Outcomes of Faricimab Treatment for Diabetic Macular Edema In Patients Previously Treated With Anti-vegf Therapy. Ophthalmic Surgery, Lasers and Imaging Retina, 2025:1-7.
  • NewsRx. Investigators from Cleveland Clinic Target Macular Edema (Early Outcomes of Faricimab Treatment for Diabetic Macular Edema In Patients Previously Treated With Anti-vegf Therapy). Health & Medicine Week. May 23, 2025; p 89.

Read more